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Objective: Age-related macular degeneration (AMD) is the leading cause of blindness in 
  western societies. Statins comprise a class of pharmacological agents that reduce plasma 
cholesterol levels, and have been shown to prevent progression of atherosclerosis and reduce 
cardiovascular mortality. The relationship between these medications and AMD has been 
evaluated in several recent studies. Herein, we examine the current evidence for an association 
between statin use and risk of AMD.
Methods: Literature database search (Medline, Scopus, and Science Citation Index Expanded) 
for articles published up to March 2010, using particular search terms.
Results: From the current evidence available, it is not safe to conclude upon the assumption 
of a protective effect of statins against age-related maculopathy and AMD.
Conclusion: There is a need for large scale prospective studies with a long follow-up period 
and accurate assessment of AMD to further explore this matter.
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Age-related macular degeneration (AMD) is the leading cause of blindness in 
  industrialized countries.1 Though some treatments slow the loss of visual function in 
later stages of age-related maculopathy (ARM),2,3 there is no effective treatment for 
ARM or for arresting its progression in its earliest phases.
The observation that AMD and atherosclerosis share common risk factors and 
pathogenetic mechanisms4 has led to the development of a hypothesis that is identified as 
the hemodynamic5 and vascular model of the pathogenesis of AMD. AMD is a vascular 
disorder characterized by impairment of choroidal perfusion of the retinal pigment 
epithelium (RPE). This model6 is now updated to incorporate recently reported evidence7 
that the changes affecting Bruch’s membrane during ageing and AMD involve lipoproteins 
processed by the RPE. The model proposes that these lipoproteins accumulate in Drusen 
and in Bruch’s membrane because the choriocapillaris does not clear them.
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) comprise 
a class of pharmacological agents that reduce plasma cholesterol levels by inhibiting 
hepatic HMG-CoA reductase, the rate-controlling enzyme in cholesterol synthesis. 
In recent years, several researchers have suggested that statins – which are known to 
be beneficial in vascular disease – also exert protective effects in AMD. It is therefore 
instructive to systematically review the evidence to date.
Search strategy and results
We searched the following computer-stored bibliographic databases: (i) Medline, 
(ii) Scopus, and (iii) Science Citation Index Expanded, for articles published up to Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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March 2010. Search terms included: “statin(s)” or “HMG-
CoA reductase inhibitor(s)” or “atorvastatin” or “cerivastatin” 
or “fluvastatin” or “lovastatin” or “mevastatin” or “pravas-
tatin” or “rivastatin” or “rosuvastatin” or “simvastatin” 
combined with “macular degeneration” or “maculopathy”. 
No language restriction was applied.
The Medline search contained 46 records, while 89 and 
58 were identified from the Scopus and the Web of Science 
database, respectively. We scanned titles and abstracts of 
the articles identified, and excluded those that were clearly 
irrelevant. We read the full text of the remaining manuscripts 
to determine whether it contained information on the topic 
of interest. We also reviewed the reference lists of articles 
with information on the topic to identify additional relevant 
studies. In total we reviewed 23 manuscripts of published 
clinical studies (Table 1).
Pathogenetic models of AMD
Two main clinical types of AMD exist, referred to as the “dry 
form” and the “wet form”. Blindness is usually associated 
with the exudative or wet form of AMD. Nonetheless, 
macular degeneration rarely results in complete blindness. 
Peripheral vision is usually not affected. Patients with early 
AMD may report slightly blurred central vision, difficulty 
in reading, color and contrast disturbances, and mild 
metamorphopsia.
The eye tissues affected by AMD are photoreceptors, 
retinal pigment epithelium (RPE), choriocapillaris (the blood 
supply to the photoreceptors and the RPE), and Bruch’s 
membrane (a thin vascular intima between the RPE and the 
choriocapillaris).8,9 Prominent extracellular lesions located 
between the RPE and Bruch’s membrane can be either focal 
or diffuse in form (Drusen and basal deposits, respectively). 
These changes predispose to the development of late stage 
ARM, referred to as age-related macular degeneration. 
It is characterized by geographic atrophy, choroidal 
neovascularization, pigment epithelial detachment, and 
fibrous scarring, which can occur in later stages.
Friedman has proposed an interesting theory on the 
pathogenesis of AMD. He stated that there should be a vascular 
and hemodynamic model. According to this model, choroidal 
vascular resistance is increased by decreased compliance of 
ocular tissues,10 as a result of progressive infiltration of the 
vessels with lipid in atherosclerosis. Moreover, as an exten-
sion of the above model, systemic hypertension, as well as 
subclinical atherosclerosis, increases the risk of neovascular 
Table 1 Demographic data of clinical studies included
Relevant study Type of  
maculopathy
Statins used Cohort size Conclusion Type of study
Martini et al ARM Simvastatin 30 Not protective Randomized clinical trial
Hall et al wet and dry AMD Any agent 392 Protective Cross sectional
McCarty et al wet and dry AMD Any agent 2594 Protective Cross sectional
Delcourt et al ARM and/or wet  
and dry AMD
Any agent 2183 Not protective Cross sectional
wilson et al 2004 wet and dry AMD Any agent 326 Protective Retrospective 
consecutive case series
Klein et al 2001 ARM Any agent 2831 Not protective Cohort
Klein et al 2003 ARM and/or wet  
and dry AMD
Any agent 2764 Not protective Cohort
van Leeuwen et al ARM Any agent 4882 Not protective Cohort
McGwin et al 2003 wet and dry AMD Any agent 6050 Protective Case control
McGwin et al 2005 ARM and/or wet  
and dry AMD
Any agent 12588 Protective Case control
Smeeth et al ARM and/or wet  
and dry AMD
Any agent 87969 Not protective Case control
Friedman et al wet and dry AMD Any agent 148 Protective Case control
Tan et al wet and dry AMD Any agent 2381 Protective Cohort
McGwin et al 2006 ARM and/or wet  
and dry AMD
Any agent 2755 Not protective Case control
Drobec et al wet and dry AMD Any agent 214 Protective Case control
etminan et al wet and dry AMD Any agent 13335 Not protective Case control
Maguire et al ARM and/or wet  
and dry AMD
Any agent 744 Not protective Cohort
Kaiserman et al wet AMD Any agent 139894 Not protective Case control
Fong et al wet AMD Any agent 79369 inconclusive Case controlClinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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and non-neovascular AMD in   case-control11 as well as in 
population-based12 epidemiological studies. The vascular 
model proposes that the increase in intravascular pressure 
results from an increase in the post-capillary resistance of 
the choroid. As a result of the increased hydrostatic pressure 
within the underlying choroidal capillary network, lipid 
material accumulates in these sites from circulating blood 
and is laid down.
There is some evidence that the RPE is the source of lipids 
in Drusen and in Bruch’s membrane. The vascular model 
proposes that impairment of choroidal perfusion compro-
mises the processing of outer segment lipid by the RPE and 
the clearance of the lipoproteins secreted by the RPE. This 
results in Drusen, pigment changes, and geographic atrophy, 
as well as calcification and fracture of Bruch’s membrane. 
Progressive accumulation of hydrophobic lipids in Bruch’s 
membrane may compromise RPE function further by decreas-
ing its hydraulic conductivity.13
The combination of elevated choriocapillary pressure 
breaks in Bruch’s membrane and secretion of vascular 
endothelial growth factor (VEGF) causes choroidal 
neovascularization.
The role of statins in AMD
Statins modify patients’ lipid profile and decrease their risk 
of coronary heart disease. They also prevent stroke and 
possibly, Alzheimer’s disease. In recent studies it has been 
hypothesized that the anti-atherosclerotic properties of statins 
may protect against the development and progression of 
ARM to AMD. If we accept the vascular model proposed 
by Friedman then, as a consequence, it is intuitive to think 
that the reduction of the lipid load inside the vessels would 
benefit the overall compliance of the ocular tissues. In this 
way, statins may lead to a virtuous spiral of lower hydrostatic 
pressure and increased blood flow in the choroidal capillary 
network, resulting in a reduced tendency to deposit lipid in 
an atherosclerotic pattern within the eye.
Another property of statins is preservation of ischemic 
vasculature.14 The activation of a protein kinase results in an 
increased production of nitric oxide that results in an improved 
choroidal blood flow and a reduced capillary drop out.
Currently, there is intense research going on regarding the 
oxidative stress and AMD. Current evidence suggests that there 
should be a protective effect of statins against maculopathy 
because of their antioxidant activity.15 The continued intake 
of statins seem to be at least equal to the prophylactic anti-
ARMD effect of multivitamin and antioxidant supplements, 
as expressed in the Blue Mountain Eye Study.
Statins have the capability of reducing the levels of 
C-reactive protein (CRP) and therefore mediate an anti-
inflammatory effect.16 It has been found that during AMD 
inflammatory cells that promote chronic inflammation are 
recruited.17 Therefore, by lowering the levels of CRP, statins 
may improve the inflammatory component of AMD.
Current evidence
The first study that investigated the aforementioned 
assumption was conducted in Italy by Martini et al in 1991.18 
In this randomized clinical study, 30 participants with AMD 
were enrolled to receive simvastatin (20 mg/day) or placebo 
for three months. The conclusion was that there was no 
statistically significant difference between the simvastatin 
and the placebo therapy in visual acuity. Unfortunately, this 
trial suffered methodological limitations such as the short 
duration of treatment and follow-up taking into account the 
slow progressive nature of the disease.
Subsequently, Della et al19 in an uncontrolled, nonran-
domized clinical trial concluded that there was no signifi-
cant difference in visual acuity between the patients taking 
statins and suffering from both raised cholesterol and signs 
of early non-neovascular macular degeneration respect the 
control group. Nonetheless, the study should be evaluated 
with caution as it was not controlled, which is considered as 
a major source of bias. For this reason, it has been excluded 
from the studies considered in the meta-analysis by Chuo 
et al20 relating to the subject.
In reference to the aforementioned analysis, this is the 
only effort to date to statistically analyze the current evidence 
on the presumed protective effects of the statins against AMD. 
In their analysis Chuo et al identified a considerable hetero-
geneity among the studies. They reached to the conclusion 
that the current evidence is not statistically strong because 
of the observational nature of the studies considered and that 
in order to reach valid statistical results we need long term 
interventional studies.
In 2001, Hall et al21 found in their study that those 
receiving statins had a reduced risk of age-related macular 
degeneration (after adjustment for coronary artery disease 
and smoking) compared to those not taking the drug. The 
odds ratio for macular degeneration was 0.14 with a wide 
confidence interval (0.02 to 0.83). In the same year, McCarty 
et al22 researched the association between statins and AMD 
in an elderly Australian population. They reported a lower 
rate of progression (3.6% versus 13%) of early AMD in those 
taking statins. Nonetheless, while the effect was large, it was 
not statistically significant. Delcourt et al23 continued in a Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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population-based study on cataract and AMD and their risk 
factors concluding that there was no association between late 
onset of AMD and the use of hypocholesterolemic drugs.
In 2003, three retrospective reviews24–26 of medical 
records reported that progression of AMD was slowed with 
statin use in a statistically significant manner. Nevertheless, 
three other population-based studies appeared during that 
period reporting that statins showed no protective effect.27–29 
McGwin et al30 conducted a large clinical study that suggested 
that subjects with ARM were less likely to have filled a statin 
prescription.
In 2005, the same author in his study31 revealed a 
statistically significant relationship between AMD and the 
use of cholesterol-lowering medications. Smeeth et al32 in 
a population-based case-control study that used data from 
the United Kingdom General Practice Research Database, 
concluded that in the short and medium term statin use is not 
associated with a decreased risk of AMD. Friedman et al33 
published a case-control study that was suggesting that 
patients on statins had a reduced risk of developing AMD.
In 2006, Tan et al34 published a cohort study (Blue 
Mountain Eye Study), and reached the conclusion that statin 
use was not associated with overall early AMD incidence 
but was protective for indistinct soft drusen, a key late AMD 
precursor lesion. McGwin et al returned with a new case-
control study that used data from the Cardiovascular Health 
Study.35 The results suggested that no association existed 
between having used cholesterol-lowering medications and 
AMD. On the contrary, there was a suggestion that statin use 
might increase the risk of AMD.
Several important studies have been published on this 
subject in 2008. Drobec et al36 published a case-control 
study that concluded that use of statins may be a protective 
factor against age-related macular degeneration, since the 
percentage of statin users was much higher in the control 
group. Nonetheless, as a confirmation of the controversy 
over the efficacy or otherwise of statins in AMD, Etminan 
et al37 published another study in which it was concluded 
that statin use may be associated with an increase in the 
risk of AMD. A large study (Age-Related Maculopathy 
Statin Study, ARMSS) is currently being conducted by 
Guymer et al however, so far only the methodology has 
been published.38
In 2009, Kaiserman et al39 investigated the association 
between the use of statins and the risk for wet age-related 
macular degeneration. It was a case-control study that 
concluded that their use is not related to a reduced risk of 
wet AMD. The latest cohort study within a multicenter, 
randomized, clinical trial, the Complications of Age-related 
Macular Degeneration Prevention Trial (CAPT), was 
conducted by Maguire et al.40 They tried to evaluate the 
impact of statin use on the incidence of advanced age-related 
macular degeneration and its components, choroidal 
neovascularization (CNV) and geographic atrophy (GA), 
among patients with bilateral large drusen. The CAPT data 
are not consistent with a strong protective effect of statins 
on the development of advanced AMD among patients with 
bilateral large drusen.
In 2010 another case control study by Fong et al41 was 
inconclusive regarding whether the statin class of drug is pro-
tective against exudative age-related macular degeneration.
Conclusion
From the current evidence available, it is not safe to conclude 
upon the assumption of a protective effect of statins against 
ARM and AMD. This is because the clinical studies already 
conducted do not provide us with adequate data in order to 
draw certain conclusions. There is a need for large scale 
prospective studies with a long follow-up period and accurate 
assessment of AMD to further explore this matter. We are 
expecting the first results from the ARMSS study to help 
elucidate the controversy over the association between statin 
use and progression of age-related macular degeneration. 
Until then, physicians need to be vigilant in ensuring that use 
of statins remains restricted to the approved indications.
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